58 related articles for article (PubMed ID: 33347529)
1. Assessment and comparison of recombinant proteins from different sources for the detection of SARS-CoV-2 infection by using protein microarray.
Qi H; Ma M; Lai D; Li Y; Zhang F; Tao SC
Acta Biochim Biophys Sin (Shanghai); 2021 Feb; 53(2):262-264. PubMed ID: 33347529
[No Abstract] [Full Text] [Related]
2. Immunoinformatic Analysis of SARS-CoV-2 Nucleocapsid Protein and Identification of COVID-19 Vaccine Targets.
Oliveira SC; de Magalhães MTQ; Homan EJ
Front Immunol; 2020; 11():587615. PubMed ID: 33193414
[TBL] [Abstract][Full Text] [Related]
3. Bioinformatics analysis of epitope-based vaccine design against the novel SARS-CoV-2.
Chen HZ; Tang LL; Yu XL; Zhou J; Chang YF; Wu X
Infect Dis Poverty; 2020 Jul; 9(1):88. PubMed ID: 32741372
[TBL] [Abstract][Full Text] [Related]
4. 3CL hydrolase-based multiepitope peptide vaccine against SARS-CoV-2 using immunoinformatics.
Jakhar R; Kaushik S; Gakhar SK
J Med Virol; 2020 Oct; 92(10):2114-2123. PubMed ID: 32379348
[TBL] [Abstract][Full Text] [Related]
5. Identification and functional analysis of the SARS-COV-2 nucleocapsid protein.
Gao T; Gao Y; Liu X; Nie Z; Sun H; Lin K; Peng H; Wang S
BMC Microbiol; 2021 Feb; 21(1):58. PubMed ID: 33618668
[TBL] [Abstract][Full Text] [Related]
6. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 Coronavirus Nucleocapsid Antigen-Detecting Half-Strip Lateral Flow Assay Toward the Development of Point of Care Tests Using Commercially Available Reagents.
Grant BD; Anderson CE; Williford JR; Alonzo LF; Glukhova VA; Boyle DS; Weigl BH; Nichols KP
Anal Chem; 2020 Aug; 92(16):11305-11309. PubMed ID: 32605363
[TBL] [Abstract][Full Text] [Related]
8. The immunodominant and neutralization linear epitopes for SARS-CoV-2.
Lu S; Xie XX; Zhao L; Wang B; Zhu J; Yang TR; Yang GW; Ji M; Lv CP; Xue J; Dai EH; Fu XM; Liu DQ; Zhang L; Hou SJ; Yu XL; Wang YL; Gao HX; Shi XH; Ke CW; Ke BX; Jiang CG; Liu RT
Cell Rep; 2021 Jan; 34(4):108666. PubMed ID: 33503420
[TBL] [Abstract][Full Text] [Related]
9. Accuracy of a nucleocapsid protein antigen rapid test in the diagnosis of SARS-CoV-2 infection.
Diao B; Wen K; Zhang J; Chen J; Han C; Chen Y; Wang S; Deng G; Zhou H; Wu Y
Clin Microbiol Infect; 2021 Feb; 27(2):289.e1-289.e4. PubMed ID: 33031947
[TBL] [Abstract][Full Text] [Related]
10. Development of a SARS-CoV-2-specific biosensor for antigen detection using scFv-Fc fusion proteins.
Kim HY; Lee JH; Kim MJ; Park SC; Choi M; Lee W; Ku KB; Kim BT; Changkyun Park E; Kim HG; Kim SI
Biosens Bioelectron; 2021 Mar; 175():112868. PubMed ID: 33281048
[TBL] [Abstract][Full Text] [Related]
11. Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA, and IgM antibodies.
Tré-Hardy M; Wilmet A; Beukinga I; Favresse J; Dogné JM; Douxfils J; Blairon L
J Med Virol; 2021 Feb; 93(2):803-811. PubMed ID: 32667733
[TBL] [Abstract][Full Text] [Related]
12. Attenuated Subcomponent Vaccine Design Targeting the SARS-CoV-2 Nucleocapsid Phosphoprotein RNA Binding Domain:
Chukwudozie OS; Chukwuanukwu RC; Iroanya OO; Eze DM; Duru VC; Dele-Alimi TO; Kehinde BD; Bankole TT; Obi PC; Okinedo EU
J Immunol Res; 2020; 2020():2837670. PubMed ID: 32964056
[TBL] [Abstract][Full Text] [Related]
13. Relative rates of non-pneumonic SARS coronavirus infection and SARS coronavirus pneumonia.
Woo PC; Lau SK; Tsoi HW; Chan KH; Wong BH; Che XY; Tam VK; Tam SC; Cheng VC; Hung IF; Wong SS; Zheng BJ; Guan Y; Yuen KY
Lancet; 2004 Mar; 363(9412):841-5. PubMed ID: 15031027
[TBL] [Abstract][Full Text] [Related]
14. Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2.
Lin L; Ting S; Yufei H; Wendong L; Yubo F; Jing Z
Virus Res; 2020 Oct; 288():198082. PubMed ID: 32621841
[TBL] [Abstract][Full Text] [Related]
15. Innate immune evasion by SARS-CoV-2: Comparison with SARS-CoV.
Bouayad A
Rev Med Virol; 2020 Nov; 30(6):1-9. PubMed ID: 32734714
[TBL] [Abstract][Full Text] [Related]
16. Cationic nanocarriers as potent adjuvants for recombinant S-RBD vaccine of SARS-CoV-2.
Lei H; Alu A; Yang J; He C; Hong W; Cheng Z; Yang L; Li J; Wang Z; Wang W; Lu G; Wei X
Signal Transduct Target Ther; 2020 Dec; 5(1):291. PubMed ID: 33311439
[No Abstract] [Full Text] [Related]
17. Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control.
Salvamani S; Tan HZ; Thang WJ; Ter HC; Wan MS; Gunasekaran B; Rhodes A
Br J Biomed Sci; 2020 Oct; 77(4):168-184. PubMed ID: 32942955
[TBL] [Abstract][Full Text] [Related]
18. Recombinant ACE2 Expression Is Required for SARS-CoV-2 To Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses.
Nascimento Conde J; Schutt WR; Gorbunova EE; Mackow ER
mBio; 2020 Dec; 11(6):. PubMed ID: 33310781
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Humoral Immune Response in Persons with Asymptomatic or Mild SARS-CoV-2 Infection, Vietnam.
Mai HK; Trieu NB; Long TH; Thanh HT; Luong ND; Huy LX; Nguyet LA; Man DNH; Anderson DE; Thanh TT; Chau NVV; Thwaites G; Wang LF; Van Tan L; Hung DT
Emerg Infect Dis; 2021 Feb; 27(2):663-666. PubMed ID: 33496647
[TBL] [Abstract][Full Text] [Related]
20. Stereotypic neutralizing V
Kim SI; Noh J; Kim S; Choi Y; Yoo DK; Lee Y; Lee H; Jung J; Kang CK; Song KH; Choe PG; Kim HB; Kim ES; Kim NJ; Seong MW; Park WB; Oh MD; Kwon S; Chung J
Sci Transl Med; 2021 Jan; 13(578):. PubMed ID: 33397677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
